Combined ACEI and ARB therapy and ICU mortality in critically ill COVID-19 patients: a retrospective cohort study
Frontiers in Pharmacology · 05.03.2026 · 17
DOI: 10.3389/fphar.2026.1714530 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.03.2026. Verfasst von Ivanny Marchant und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Modelamiento en Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The clinical safety and potential benefits of renin–angiotensin–aldosterone system (RAAS) inhibitors in COVID-19 remain debated, particularly in critically ill populations. Evidence on combined angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy is limited, and the potential interaction with acid–base status has not been sufficiently explored.
Methods
We conducted a retrospective cohort study including adults with PCR-confirmed COVID-19 admitted to the intensive care unit (ICU) at Hospital Dr. Gustavo Fricke (Chile) between March 2020 and December 2021. Patients were categorized according to RAAS therapy at admission (none, ACEI only, ARB only, ACEI + ARB) and arterial bicarbonate (HCO 3 − ) levels (low <21 mEq/L, normal 21–27 mEq/L, high >27 mEq/L). Changes in HCO 3 − during the first 48 h were evaluated. The primary outcome was in-hospital mortality; secondary outcomes included ICU length of stay and duration of mechanical ventilation. Group comparisons used chi-square and non-parametric tests.
Results
Of 2,838 hospitalized patients, 671 required ICU admission and 655 had complete data for analysis. Overall ICU mortality was 34.2%. Combined ACEI + ARB therapy was associated with lower mortality (16.9%) compared with no RAAS blockade (38.3%; p < 0.05), whereas ACEI or ARB monotherapy showed no significant association. Among patients with low or normal admission HCO 3 − levels, early increases within 48 h were associated with reduced mortality. Patients with elevated baseline HCO 3 − who survived experienced longer ICU stays and prolonged mechanical ventilation.
Discussion
In this observational ICU cohort, dual RAAS blockade was associated with lower in-hospital mortality, although causal inference is limited by the retrospective design and incomplete pharmacologic exposure data. Early bicarbonate increase may reflect renal adaptive capacity and has potential prognostic value. Prospective controlled studies are needed to clarify the clinical relevance of RAAS modulation and metabolic biomarkers in severe COVID-19.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorio de Modelamiento en Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
- Unidad de Estudios Clínicos, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
- Unidad de Cuidados Intensivos, Hospital Dr. Gustavo Fricke, Viña del Mar, Chile.
- Laboratorio de Estructura y Función Celular, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
- Escuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Valparaíso, Chile.
Zitieren
APA
Marchant, I., Balcazar, G., Pozo, V., Olivero, P., Rodríguez, B., Castillo, R., & Espinoza, H. (2026). Combined ACEI and ARB therapy and ICU mortality in critically ill COVID-19 patients: a retrospective cohort study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1714530
Vancouver
Marchant I, Balcazar G, Pozo V, Olivero P, Rodríguez B, Castillo R, et al. Combined ACEI and ARB therapy and ICU mortality in critically ill COVID-19 patients: a retrospective cohort study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1714530
BibTeX
@article{Marchant2026,
author = {Marchant, Ivanny and Balcazar, Gloria and Pozo, Valentina and Olivero, Pablo and Rodríguez, Belén and Castillo, Romina and Espinoza, Hilda},
title = {Combined ACEI and ARB therapy and ICU mortality in critically ill COVID-19 patients: a retrospective cohort study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1714530}
}
EUVIMED